- Home
- INSM vs LOGI Comparison
INSM vs LOGI Comparison
Compare INSM & LOGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- LOGI
- Stock Information
- Founded
- INSM 1988
- LOGI 1981
- Country
- INSM United States
- LOGI Switzerland
- Employees
- INSM N/A
- LOGI N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- LOGI Computer peripheral equipment
- Sector
- INSM Health Care
- LOGI Technology
- Exchange
- INSM Nasdaq
- LOGI Nasdaq
- Market Cap
- INSM 14.3B
- LOGI 13.5B
- IPO Year
- INSM 2000
- LOGI 1997
- Fundamental
- Price
- INSM $72.00
- LOGI $85.02
- Analyst Decision
- INSM Strong Buy
- LOGI Hold
- Analyst Count
- INSM 16
- LOGI 9
- Target Price
- INSM $95.36
- LOGI $100.14
- AVG Volume (30 Days)
- INSM 1.5M
- LOGI 562.2K
- Earning Date
- INSM 05-08-2025
- LOGI 04-28-2025
- Dividend Yield
- INSM N/A
- LOGI 1.62%
- EPS Growth
- INSM N/A
- LOGI 39.12
- EPS
- INSM N/A
- LOGI 4.25
- Revenue
- INSM $363,707,000.00
- LOGI $4,556,032,000.00
- Revenue This Year
- INSM $30.31
- LOGI $7.57
- Revenue Next Year
- INSM $118.39
- LOGI $4.54
- P/E Ratio
- INSM N/A
- LOGI $19.85
- Revenue Growth
- INSM 19.17
- LOGI 7.28
- 52 Week Low
- INSM $21.92
- LOGI $74.72
- 52 Week High
- INSM $84.91
- LOGI $105.65
- Technical
- Relative Strength Index (RSI)
- INSM 36.27
- LOGI 31.19
- Support Level
- INSM $76.05
- LOGI $83.02
- Resistance Level
- INSM $79.12
- LOGI $92.70
- Average True Range (ATR)
- INSM 2.62
- LOGI 1.25
- MACD
- INSM -0.37
- LOGI -0.62
- Stochastic Oscillator
- INSM 0.63
- LOGI 20.66
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About LOGI Logitech International S.A.
Logitech was founded in 1981 and is headquartered in Lausanne, Switzerland. The company specializes in designing and manufacturing computer peripherals such as mice, keyboards, webcams, conference room cameras, headsets, and music-related products like wireless speakers.